Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 2,102 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Coronary Artery Disease
Interventions: Nicardipine, Sterile Saline; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myasthenia Gravis
Interventions: IGIV-C, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more

Conditions: HIV Infections
Interventions: Romidepsin, Placebo for Romidepsin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165, Placebo, MTX, Folic (or folinic) acid; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more

Conditions: Knee Arthropathy
Interventions: preop ACB, followed by Intra-articular block during TKA surgery, preop ACB+IPACK block, preop ACB+IPACK block, followed by Intra-articular block during TKA surgery; Other
Lead sponsor: University of Louisville; Other
Eligibility: 22 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions: Ranibizumab, Saline; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 67
States / cities: Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more

Conditions: Subarachnoid Hemorrhage
Interventions: Normal Saline, Nicardipine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Saline Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Jamaica Plain, Massachusetts

Conditions: High Grade Glioma
Interventions: NK cells; Biological
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 12 Months to 39 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Neuroendocrine Tumors in Lung
Interventions: Lanreotide (Autogel formulation), Placebo, Best Supportive Care; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Healthy
Interventions: HEPLISAV and/or Placebo, Engerix-B; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 2,452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 29
States / cities: Huntsville, Alabama • San Diego, California • Santa Ana, California + 26 more

Conditions: HIV Infections
Interventions: DNA Nat-B env, DNA CON-S env, DNA Mosaic env, MVA-CMDR, Placebo for DNA Nat-B env, Placebo for DNA CON-S env, Placebo for DNA Mosaic env, Placebo for MVA-CMDR; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 2 more

Conditions: Norovirus Acute Gastroenteritis
Interventions: mRNA-1403, mRNA-1405, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more

Conditions: Post-surgical Pain, Total Knee Arthroplasty, Foot/Ankle Surgery, Catheterization for Postop Analgesia
Interventions: ropivacaine 0.2%; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions: Rejuveinix (RJX) Active Comparator, Placebo Comparator; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Houston, Texas • New Braunfels, Texas

Conditions: Hepatorenal Syndrome
Interventions: Terlipressin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions: Levosimendan, Matching Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 16
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more

Conditions: Rapid Atrial Fibrillation, Heart Rate Control
Interventions: Dexmedetomidine Hydrochloride, Normal Saline; Drug · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions: Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo; Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Rotator Cuff Tear, Pain, Postoperative
Interventions: liposomal bupivicaine, Dexamethasone; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Avon, Indiana

Search by objective public record fields.

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine

Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load

Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis

Pain Levels and Opioid Usage in Three Nerve Block Cohorts in Primary TKA

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage

Study of Tirzepatide for Recovery and Alcohol Use Management

Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks

Tolerability and Efficacy of RJX in Patients With COVID-19

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

Impact of Liraglutide 3.0 on Body Fat Distribution

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Controlling Rapid Atrial Fibrillation With Dexmedetomidine

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Single Shot Liposomal Bupivicaine in Rotator Cuff Surgery